Potential QT-prolonging drug-drug interactions in cardiovascular disease patients
DOI:
https://doi.org/10.1590/Keywords:
QT interval, QT prolongation, Drug-induced, Drug-drug interactions, Cardiac patients, Patient safetyAbstract
The study aimed to assess the prevalence and characteristics of potential drug-drug interactions (pDDIs) that increase the risk of QT prolongation, in a population of cardiovascular disease patients. An observational retrospective study was conducted at a cardiology ward. A total of 351 patients were included in the analysis, with almost equal gender distribution (female 48.4%) and mean age 70±10 years. In the total set of tested drug pairs (5620), QT-prolonging pDDIs were identified in 13 drug pairs on admission. The highest frequency was observed for ciprofloxacin (involved in 5 pDDIs), followed by propafenone (4 pDDIs) and beta2-agonists (4 pDDIs). The pharmacodynamic mechanism was involved in all pDDIs. The study revealed a low prevalence of QT-prolonging pDDIs on admission to the cardiology ward, about 3% in the studied population. However, given that underlying heart disease is a significant risk factor for the occurrence of QTc prolongation, the additional risk for acquired QT prolongation should not be neglected. Due to serious consequences caused by QT prolongation and TdP, the key role of health professionals is to identify predisposed patients and to recognize pDDIs involving QT-prolonging agents. Hence, patients’ modifiable risk factors for QT prolongation should be minimized, if not eliminated.
Downloads
References
Ambhore A, Teo SG, Bin Omar AR, Poh KK. Importance of QT interval in clinical practice. Singapore Med J. 2014;55(12):607-11; quiz 12.
Armahizer MJ, Seybert AL, Smithburger PL, Kane-Gill SL. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care. 2013;28(3):243-9.
Cohagan B, Brandis D 2022. Torsade de Pointes. StatPearls Publishing LLC.
Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy. 2003;23(7):881-908.
Fernandes FM, Da Silva Paulino AM, Sedda BC, Da Silva EP, Martins RR, Oliveira AG. Assessment of the risk of QT-interval prolongation associated with potential drug-drug interactions in patients admitted to Intensive Care Units. Saudi Pharm J. 2019;27(2):229-34.
Heemskerk CPM, Pereboom M, Van Stralen K, Berger FA, Van Den Bemt P, Kuijper AFM, et al. Risk factors for QTc interval prolongation. Eur J Clin Pharmacol. 2018;74(2):183-91.
Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9(6):364-77.
Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol. 2013;76(1):48-57.
Kaab S, Pfeufer A, Hinterseer M, Nabauer M, Schulze-Bahr E. Long QT syndrome. Why does sex matter? Z Kardiol. 2004;93(9):641-5.
Khan Q, Ismail M, Haider I. High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units. Postgrad Med. 2018;130(8):660-65.
Khan Q, Ismail M, Haider I, Haq IU, Noor S. QT interval prolongation in hospitalized patients on cardiology wards: a prospective observational study. Eur J Clin Pharmacol . 2017a;73(11):1511-18.
Khan Q, Ismail M, Khan S. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study. BMC Pharmacol Toxicol. 2017b;18(1):75.
Letsas KP, Efremidis M, Kounas SP, Pappas LK, Gavrielatos G, Alexanian IP, et al. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors. Clin Res Cardiol. 2009;98(4):208-12.
Meid AD, Bighelli I, Machler S, Mikus G, Carra G, Castellazzi M, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-64.
Niemeijer MN, Van Den Berg ME, Leening MJ, Hofman A, Franco OH, Deckers JW, et al. Declining incidence of sudden cardiac death from 1990-2010 in a general middle-aged and elderly population: The Rotterdam Study. Heart Rhythm. 2015;12(1):123-9.
Riad FS, Davis AM, Moranville MP, Beshai JF. Drug-Induced QTc Prolongation. Am J Cardiol. 2017;119(2):280-83.
Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-22.
Savić N, Gojković-Bukarica L. Long QT syndrome: genetic implications and drug influence. Vojnosanit Pregl. 2008;65(4):308-12.
Schachtele S, Tumena T, Gassmann KG, Fromm MF, Maas R. Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients. PLoS One. 2016;11(5):e0155649.
Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, et al. Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf. 2015;38(2):197-206.
Smithburger PL, Kane-Gill SL, Seybert AL. Drug-drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved. Int J Pharm Pract. 2012;20(6):402-8.
Smithburger PL, Seybert AL, Armahizer MJ, Kane-Gill SL. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions. Expert Opin Drug Saf . 2010;9(5):699-712.
Surawicz B, Knilans T 2001. Chou’s Electrocardiography in Clinical Practice: Adult and Pediatric, Saunders.
Thomas SH, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol . 2016;81(3):420-7.
Tisdale JE, Wroblewski HA, Overholser BR, Kingery JR, Trujillo TN, Kovacs RJ. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. Drug Saf . 2012;35(6):459-70.
Van Der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, Van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol . 2009;67(3):347-54.
Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39(1):16-25.
Wisniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials. BMC Pharmacol Toxicol . 2016;17:12.
Woosley RL, Black K, Heise CW, Romero K. CredibleMeds.org: What does it offer? Trends Cardiovasc Med. 2018;28(2):94-9.
Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore). 2003;82(4):282-90.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
How to Cite
Funding data
-
University of Belgrade
Grant numbers 451-03-65/2024-03/200161;451-03-66/2024-03/200161
